The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by ...

The "I’m Ready" campaign initially launched in the summer of 2021, two years after Mavenclad’s FDA approval ... from other MS infusions and daily pills by requiring only about 16 to 20 ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS).

Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company’s goal is to achieve a 50-50 split ...

On approval, ozanimod would be set to compete with other drugs such as Merck KGaA’s Mavenclad (cladribine ... The latter are all pills and thus a more convenient alternative than the injected ...

The effort is designed to raise awareness of RMS — and which is the most common form of MS — as well as the treatment option of Mavenclad (cladribine) tablets, which are produced by the healthcare ...

US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...